High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin (original) (raw)

References

  1. Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA, Alvarado-Cabrero I, Rico-Méndez FG, Javier KG (2010) Case–control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241–251. doi:10.1002/ajim.20780
    PubMed Google Scholar
  2. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12):2984–2987
    Article CAS PubMed Google Scholar
  3. Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D, Corona-Cruz JF (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027–1032. doi:10.1038/bjc.2012.44
    Article CAS PubMed Central PubMed Google Scholar
  4. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx™ in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11(6):697–700
    Article CAS PubMed Google Scholar
  5. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713–722
    Article PubMed Google Scholar
  6. Head HW, Dodd GD 3rd, Bao A, Soundararajan A, Garcia-Rojas X, Prihoda TJ, McManus LM, Goins BA, Santoyo CA, Phillips WT (2010) Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 255(2):405–414. doi:10.1148/radiol.10090714
    Article PubMed Central PubMed Google Scholar
  7. Health and Safety Executive (2013) Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968–2011. Health and Safety Executive, UK
    Google Scholar
  8. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3):118–120
    Article CAS PubMed Google Scholar
  9. Ji S, Zheng Y, Shao G, Zhou Y, Liu S (2013) Integrin αvβ3-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy. Theranostics 3(11):816–830. doi:10.7150/thno.6989
    Article CAS PubMed Central PubMed Google Scholar
  10. Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 14(2):164–171. doi:10.1016/j.cllc.2012.09.003
    Article CAS PubMed Google Scholar
  11. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345–3352. doi:10.1200/JCO.2011.40.8120
    Article CAS PubMed Central PubMed Google Scholar
  12. Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308–313. doi:10.1016/j.lungcan.2008.09.008
    Article PubMed Google Scholar
  13. Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469–477. doi:10.1097/JTO.0b013e318283da3e
    Article CAS PubMed Google Scholar
  14. Arrieta O, López-Macías D, Mendoza-García VO, Bacon-Fonseca L, Muñoz-Montalvo W, Macedo-Pérez EO,Muñiz-Hernández S, Blake-Cerda M, Corona-Cruz JF (2014) A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73(5):975–982. doi:10.1007/s00280-014-2429-5
  15. Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G (2013) Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 39(4):328–339. doi:10.1016/j.ctrv.2012.11.004
    Article PubMed Google Scholar
  16. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441–3444
    CAS PubMed Google Scholar
  17. Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 12(5):806–811. doi:10.1510/icvts.2010.255901
    Article PubMed Google Scholar
  18. Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44–50. doi:10.1038/sj.bjc.6604421
    Article PubMed Central PubMed Google Scholar
  19. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 28:6881–6889
    Article Google Scholar
  20. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644
    Article CAS PubMed Google Scholar

Download references